A study suggests that the availability of orphan drugs varies significantly between different...
- Research shows differences in orphan drug availability in Europe
- The state of US somatic cell therapy facilities
- Tremfya approval: increasing options for psoriasis treatment
- Blockbuster immunology drugs facing patent expiry and biosimilar competition
- Takeda makes fourth offer of £44.3bn for Shire takeover
Research shows differences in orphan drug availability in Europe
A study suggests that the availability of orphan drugs varies significantly between different countries in Europe.
Baccinex Awards Telstar the Design and Construction of Aseptic Filling Process Plant
Baccinex has entrusted Telstar with the design and construction of a cleanroom installation to accommodate an aseptic and lyophilised filling process line, enlarging the existing pharmaceutical plant in the Switzerland region of Jura.
Tremfya approval: increasing options for psoriasis treatment
Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya to MorphoSys in these respective regions.
Why Choose Interlanguage for Your Translation Needs?
It is through communication that a company presents itself to the world. They are its voice and create its image, anywhere and in any language. Wherever you want to get your message across, interlanguage is by your side.
Blockbuster immunology drugs facing patent expiry and biosimilar competition
Despite the highly competitive nature of the immunology drugs market there are several well-established blockbuster drugs that dominate in terms of revenue.
Takeda makes fourth offer of £44.3bn for Shire takeover
Takeda Pharmaceutical Company has put forward a fourth offer to acquire Shire, a day after the Irish biopharmaceutical company best known for ADHD drug Adderall rejected a previous offer.
Pfizer’s Trumenba gets breakthrough status for meningococcal disease
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Pfizer’s Trumenba for meningococcal B disease in children aged between one and nine.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.